Joint venture is expected to leverage Astellas' expertise in cell therapy R&D and Yaskawa’s robotics technology to enhance ...

Astellas Pharma and Yaskawa have agreed to form a JV that will focus on developing a cell therapy product manufacturing ...

The agreement—powered by YASKAWA's Maholo robot—aims to address challenges in production and commercialization while offering ...

With the power of robotics and the personalized medicine expertise of one of Japan's top drugmakers, Astellas Pharma and Yaskawa Electric Corporation are setting off on a joint venture to help stre | ...

Astellas and Yaskawa are establishing a joint venture for the development of a cell therapy product manufacturing platform ...

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and YASKAWA Electric Corporation (TSE: 6506, President and CEO; Masahiro Ogawa, "YASKAWA") signed a definitive agreement ...

The JV will leverage a dual-arm robot known as Maholo, developed by Yaskawa subsidiary the Robotic Biology Institute. The JV provides access to the platform for academic institutions and startups ...

Astellas, YASKAWA agree to establish a JV focused on cell therapy manufacturing: Tokyo Friday, March 7, 2025, 10:00 Hrs [IST] Astellas Pharma Inc. and YASKAWA Electric Corporation ...

The planned joint venture will leverage Astellas' expertise in R&D and manufacturing for cell therapy and the dual arm robot "Maholo," developed by YASKAWA's subsidiary, Robotic Biology Institute.

YASKAWA's subsidiary, Robotic Biology Institute, has developed Maholo. In addition, the JV will offer platform access to startups and academic institutions, fostering collaboration and innovation ...